Locus Biosciences - About the company
Locus Biosciences is a series B company based in Raleigh (United States), founded in 2015 by Dave Ousterout, Rodolphe Barrangou, Chase Beisel, Charles Gersbach and Paul Garofolo. It operates as a Developer of therapeutics for infectious disease and inflammatory indications. Locus Biosciences has raised $67.3M in funding from investors like Illumina, Tencent and Viking Global Investors. The company has 326 active competitors, including 135 funded and 57 that have exited. Its top competitors include companies like CRISPR Therapeutics, Spero Therapeutics and Verve.
Company Details
Developer of therapeutics for infectious disease and inflammatory indications. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria and enables the development of antimicrobials for infectious diseases.
- Website
- www.locus-bio.com/
- Social
- Email ID
- *****@locus-bio.com
- Registered Address
- Morrisville, North Carolina
Key Metrics
Founded Year
2015
Location
Raleigh, United States
Stage
Series B
Total Funding
$67.3M in 12 rounds
Latest Funding Round
Ranked
21st among 326 active competitors
Employee Count
74 as on Dec 31, 2022
Investment & Acquisitions
Similar Companies
Legal entities associated with Locus Biosciences
Locus Biosciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
LOCUS BIOSCIENCES, INC CIN: 474084065 , United States, Active | - | 48 (As on Dec 31, 2024) | - |
Sign up to download Locus Biosciences' company profile
Locus Biosciences's funding and investors
Locus Biosciences has raised a total funding of $67.3M over 12 rounds. Its first funding round was on Feb 05, 2016. Its latest funding round was a Grant (prize money) round on Jan 23, 2024 for $*****. 1 investor participated in its latest round. Locus Biosciences has 15 institutional investors.
Here is the list of recent funding rounds of Locus Biosciences:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 23, 2024 | 2317851 | Grant (prize money) | 8636084 | 8183759 | 3204575 | 3839446 |
May 18, 2022 | 9788092 | Series B | 3148309 | 5552478 | 6558082 | |
Oct 20, 2021 | 9600358 | Conventional Debt | 6042499 | 6294032 | 3828111 |
Access funding benchmarks and valuations. Sign up today!View details of Locus Biosciences's funding rounds and investors
Locus Biosciences' founders and board of directors
Founder? Claim ProfileThe founders of Locus Biosciences are Dave Ousterout, Rodolphe Barrangou, Chase Beisel, Charles Gersbach and Paul Garofolo.
Here are the details of Locus Biosciences' key team members:
- Dave Ousterout: Co-Founder & CTO of Locus Biosciences and founder of 1 other company. Contact Info: 1 email address
- Rodolphe Barrangou: Co-Founder & Chief Strategy Officer of Locus Biosciences and founder of 1 other company.
- Chase Beisel: Co-Founder of Locus Biosciences and founder of 1 other company.
- Charles Gersbach: Co-Founder of Locus Biosciences.
- Paul Garofolo: Co-Founder & CEO of Locus Biosciences. Contact Info: 1 email address
View details of Locus Biosciences's Founder profiles and Board Members
Locus Biosciences' employee count trend
Locus Biosciences has 74 employees as of Dec 22. The total employee count is 1.0% lower than what it was in Dec 21. Here is Locus Biosciences's employee count trend over the years:
Uncover Locus Biosciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Locus Biosciences's Competitors and alternates
Top competitors of Locus Biosciences include CRISPR Therapeutics, Spero Therapeutics and Verve. Here is the list of Top 10 competitors of Locus Biosciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | CRISPR Therapeutics 2013, Basel (Switzerland), Public | Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 74/100 | |
2nd | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 72/100 | |
3rd | _1557388532154.png?devicePixelRatio=2&height=30&width=30){kind=logo} Verve 2018, Cambridge (United States), Acquired | Developer of gene-editing therapies for treating coronary artery disease | $216M | 70/100 | |
4th | eGenesis 2015, Cambridge (United States), Series D | Developer of a gene transplantation platform for humanizing pig cells | $481M | 68/100 | |
5th | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | 67/100 | |
6th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA-editing technologies for precision medicine | $4M | 67/100 | |
7th | Melinta Therapeutics 2000, Morristown (United States), Acquired | Developer of bacterial ribosome-targeting drugs for MDR infections | $186M | 67/100 | |
8th | Precision BioSciences 2006, Durham (United States), Public | Developer of gene editing therapies to treat rare genetic diseases | $136M | 65/100 | |
9th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
10th |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 64/100 | |
21st | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Locus Biosciences's competitors? Click here to see the top ones
Locus Biosciences's Investments and acquisitions
Locus Biosciences has acquired EpiBiome. Locus Biosciences has not made any investments as of now.Reports related to Locus Biosciences
Here is the latest report on Locus Biosciences's sector:
News related to Locus Biosciences
Filter this listMedia has covered Locus Biosciences for a total of 3 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
•
•
•
EverGlade Consulting hires Joe Larsen as managing directorConsulting•May 06, 2024•EverGlade, Locus Biosciences
•
•
Synbio Company Replay Launches with $55M in Seed FundingGenomeWeb•Jul 25, 2022•KKR, OMX Ventures, Artis Ventures, Lansdowne Partners and 13 others
•
RTP’s Locus Biosciences closes $35M Series B, investors include J&J and TencentWRAL TechWire•May 18, 2022•Locus Biosciences, Tencent, Viking Global Investors, Artis Ventures and 3 others
•
Hercules Capital Provides $25MM Credit Facility to Locus BiosciencesABFJournal•Oct 20, 2021•Locus Biosciences, Hercules Capital
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Locus Biosciences
Explore our recently published companies
- Recruiter Media - United States based, 2001 founded, Unfunded company
- Jack Bunneys - Barking based, 1958 founded, Unfunded company
- Shreekrishna Caterers - Mumbai based, 2024 founded, Unfunded company
- Prestige Group - Bengaluru based, Unfunded company
- OPPY Financial - New York based, Unfunded company
- Wind Fisher - Les Adrets based, 2022 founded, Unfunded company
